{"id":"incretin-based-therapy","safety":{"commonSideEffects":[{"rate":"10–40","effect":"Nausea"},{"rate":"5–15","effect":"Vomiting"},{"rate":"10–20","effect":"Diarrhea"},{"rate":"5–15","effect":"Hypoglycemia"},{"rate":"5–10","effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Incretin hormones account for 50–70% of the postprandial insulin secretion in healthy individuals. Incretin-based therapies work by either mimicking GLP-1 receptor agonists (GLP-1 RAs) or inhibiting dipeptidyl peptidase-4 (DPP-4) to prevent degradation of endogenous incretins. Both approaches increase glucose-dependent insulin secretion and suppress glucagon, thereby lowering blood glucose levels in a glucose-dependent manner.","oneSentence":"Incretin-based therapy enhances insulin secretion by mimicking or prolonging the action of incretin hormones (GLP-1 and GIP) that are released in response to oral glucose intake.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:48:39.404Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT06930495","phase":"","title":"The Effect of Adiposity on Muscle and Microvascular Function in HFpEF","status":"ENROLLING_BY_INVITATION","sponsor":"University of Texas Southwestern Medical Center","startDate":"2024-12-10","conditions":"Heart Failure With Preserved Ejection Fraction (HFPEF)","enrollment":95},{"nctId":"NCT07462663","phase":"","title":"SHAPE-ENDO: Multimodal Pre-Surgical Optimization in Patients With Obesity and Early-Stage Endometrial Cancer","status":"NOT_YET_RECRUITING","sponsor":"Hospital Universitari de Bellvitge","startDate":"2026-05","conditions":"Endometrial Cancer, Endometrial Cancer Stage I, Atypical Endometrial Hyperplasia and Endometrial Carcinoma Stage I","enrollment":82},{"nctId":"NCT07417618","phase":"","title":"INcreTin-based thERapies for Cardiovascular Event PrevenTion in Patients With and Without ASCVD (INTERCEPT-ASCVD)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2026-01-27","conditions":"Type 2 Diabetes, Overweight, ASCVD","enrollment":60000},{"nctId":"NCT07409831","phase":"NA","title":"Incretin-based Therapies, Nutrition, and Physical Activity","status":"NOT_YET_RECRUITING","sponsor":"Laval University","startDate":"2026-03","conditions":"Obesity & Overweight, Cardiometabolic Conditions","enrollment":120},{"nctId":"NCT07058155","phase":"PHASE4","title":"Optimizing Portal Hypertension With TIPS and Interval Metabolic Surgery for Advanced Liver Disease","status":"RECRUITING","sponsor":"The Cleveland Clinic","startDate":"2025-12-17","conditions":"Liver Cirrhoses, Portal Hypertension Related to Cirrhosis, Severe Obesity","enrollment":70},{"nctId":"NCT07284511","phase":"PHASE2, PHASE3","title":"A Clinical Trial Using Tirzepatide to Help Adults With Type 1 Diabetes Automatically Control Their Blood Sugar","status":"NOT_YET_RECRUITING","sponsor":"Melissa-Rosina Pasqua","startDate":"2026-01-05","conditions":"Type 1 Diabetes, Type 1 Diabetes Mellitus, T1D","enrollment":105},{"nctId":"NCT06533527","phase":"PHASE4","title":"Holding vs. Continuing Incretin-based Therapies Before Upper Endoscopy","status":"COMPLETED","sponsor":"The Cleveland Clinic","startDate":"2024-07-31","conditions":"Diabetes Mellitus, Type 2, Obesity, Gastroparesis","enrollment":69},{"nctId":"NCT06374875","phase":"PHASE4","title":"Fibrosis Lessens After Metabolic Surgery","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2024-07-11","conditions":"Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD), Non-Alcoholic Fatty Liver Disease, Metabolic Dysfunction-Associated Steatohepatitis (MASH)","enrollment":120},{"nctId":"NCT06959784","phase":"PHASE4","title":"Assessing Incretin Therapy for Cardiovascular Risk Reduction and Diabetes Remission( ITCRDR Study)","status":"ENROLLING_BY_INVITATION","sponsor":"China-Japan Friendship Hospital","startDate":"2024-01-01","conditions":"Diabetes Mellitus, Cardiovascular Diseases, Cerebrovascular Disease","enrollment":142},{"nctId":"NCT06950684","phase":"NA","title":"Impact of Protein Supplementation and Resistance Training on Body Composition, Functional Parameters, Metabolic Adaptation, and Nitrogen Balance in Adults Aged 45 Years and Older With Overweight or Obesity Receiving Incretin-based Medications","status":"NOT_YET_RECRUITING","sponsor":"Assuta Medical Center","startDate":"2025-07-01","conditions":"Obesity, Overweight (BMI > 25), Weight Loss","enrollment":180},{"nctId":"NCT06431308","phase":"NA","title":"Nutritional Therapy to Incretin-based Anti-obesity Medications in the Management of Gastrointestinal Adverse Events","status":"RECRUITING","sponsor":"Ariel University","startDate":"2025-01-30","conditions":"Obesity; Drug","enrollment":120},{"nctId":"NCT06803888","phase":"PHASE4","title":"Bariatric Surgery vs. Semaglutide vs. Tirzepatide","status":"RECRUITING","sponsor":"Ali Aminian","startDate":"2025-01-29","conditions":"Obesity and Obesity-related Medical Conditions","enrollment":125},{"nctId":"NCT02029846","phase":"PHASE4","title":"Glycemia in Diabetic Elders Trial","status":"TERMINATED","sponsor":"Johns Hopkins University","startDate":"2013-04","conditions":"Type 2 Diabetes Mellitus","enrollment":2},{"nctId":"NCT02671864","phase":"NA","title":"Incretin-mimetic Hypoglycemic Drugs and Severe Retinopathy","status":"UNKNOWN","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2016-04-11","conditions":"Type 2 Diabetes","enrollment":7200},{"nctId":"NCT01879228","phase":"NA","title":"Effect of Chronic Incretin-based Therapy in Cystic Fibrosis","status":"COMPLETED","sponsor":"University of Pennsylvania","startDate":"2013-06","conditions":"Cystic Fibrosis, Pancreatic Insufficiency","enrollment":26},{"nctId":"NCT02898506","phase":"PHASE2","title":"Incretin-based Therapy in Late Preclinical Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT02611232","phase":"PHASE2","title":"Incretin-based Therapy in Preclinical Type 1 Diabetes in Adults","status":"UNKNOWN","sponsor":"University of Oulu","startDate":"2015-12","conditions":"Type 1 Diabetes","enrollment":42},{"nctId":"NCT02908087","phase":"PHASE2","title":"Incretin-based Therapy in Early Diagnosed Type 1 Diabetes","status":"COMPLETED","sponsor":"University of Oulu","startDate":"2016-03","conditions":"Type 1 Diabetes","enrollment":13},{"nctId":"NCT03103009","phase":"PHASE1","title":"Treatment Plan for an Individual Patient With Pasireotide for Hyperinsulinemic Hypoglycemia","status":"COMPLETED","sponsor":"University of Colorado, Denver","startDate":"2017-03-22","conditions":"Hyperinsulinemic Hypoglycemia, Post Gastrointestinal Tract Surgery Hypoglycaemia","enrollment":1},{"nctId":"NCT02694575","phase":"","title":"The Impact of Glucose Lowering Therapies on Circulating Endothelial Progenitor Cells and Its Mobilising Factor Stromal Derived Factor-1α in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"University of Leicester","startDate":"2015-03-01","conditions":"Diabetes Mellitus, Type 2, Cardiovascular Diseases","enrollment":241},{"nctId":"NCT02324842","phase":"NA","title":"Effect of Combined Incretin-Based Therapy Plus Canagliflozin on Glycemic Control and the Compensatory Rise in Hepatic Glucose Production in Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2014-11","conditions":"Type 2 Diabetes Mellitus","enrollment":45},{"nctId":"NCT02060383","phase":"PHASE4","title":"Study of Management of Pasireotide-induced Hyperglycemia in Adult Patients With Cushing's Disease or Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-05-23","conditions":"Cushing's Disease, Acromegaly","enrollment":249},{"nctId":"NCT01503112","phase":"","title":"Predicting Response to Incretin Based Agents in Type 2 Diabetes","status":"COMPLETED","sponsor":"Royal Devon and Exeter NHS Foundation Trust","startDate":"2011-05","conditions":"Type2 Diabetes","enrollment":957},{"nctId":"NCT02476760","phase":"","title":"Incretin-based Drugs and Acute Pancreatitis","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Diabetes Mellitus, Type 2","enrollment":1417914},{"nctId":"NCT02882477","phase":"PHASE2, PHASE3","title":"Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2016-12","conditions":"Diabetes Mellitus, Iron Metabolism Disorders, Gastroduodenal Ulcer","enrollment":20},{"nctId":"NCT02456428","phase":"","title":"Incretin-based Drugs and the Risk of Heart Failure","status":"COMPLETED","sponsor":"Canadian Network for Observational Drug Effect Studies, CNODES","startDate":"2014-03","conditions":"Type 2 Diabetes Mellitus","enrollment":1499650},{"nctId":"NCT02026024","phase":"","title":"Incretin Based Therapy for Poorly Controlled Type 2 Diabetic Patients","status":"COMPLETED","sponsor":"Chang Gung Memorial Hospital","startDate":"2013-10","conditions":"Type 2 Diabetes Mellitus","enrollment":10},{"nctId":"NCT01744236","phase":"PHASE4","title":"SAFEGUARD: Pleiotropic Effects of Incretin Based Therapies","status":"COMPLETED","sponsor":"Amsterdam UMC, location VUmc","startDate":"2013-04","conditions":"Type 2 Diabetes","enrollment":70},{"nctId":"NCT01678742","phase":"NA","title":"Effects of Jeju Red Horsehead Fish-based, High Protein Diet on Satiety and Incretin Hormones in Diabetes Patients","status":"COMPLETED","sponsor":"Jeju National University Hospital","startDate":"2012-08","conditions":"Diabetes Mellitus, Obesity","enrollment":40},{"nctId":"NCT01681550","phase":"NA","title":"A Cohort Study of Incretin-based Therapy Combined With Insulin in Type 2 Diabetic Patients for 5 Years","status":"UNKNOWN","sponsor":"Nagaoka Red Cross Hospital","startDate":"2012-10","conditions":"Type 2 Diabetes Mellitus","enrollment":500}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":285,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glucagon-like Peptide-1 Receptor Agonist"],"phase":"marketed","status":"active","brandName":"Incretin-based therapy","genericName":"Incretin-based therapy","companyName":"Nagaoka Red Cross Hospital","companyId":"nagaoka-red-cross-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Incretin-based therapy enhances insulin secretion by mimicking or prolonging the action of incretin hormones (GLP-1 and GIP) that are released in response to oral glucose intake. Used for Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}